MENU
+Compare
ICAD
Stock ticker: NASDAQ
AS OF
Jul 1, 04:53 PM (EDT)
Price
$3.72
Change
-$0.09 (-2.36%)
Capitalization
42.43M

ICAD iCAD Forecast, Technical & Fundamental Analysis

icad Inc is a medical technology company providing cancer detection and therapy solutions... Show more

ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ICAD with price predictions
Jun 30, 2025

Momentum Indicator for ICAD turns positive, indicating new upward trend

ICAD saw its Momentum Indicator move above the 0 level on June 26, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICAD advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 127 cases where ICAD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.274) is normal, around the industry mean (24.307). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.499) is also within normal values, averaging (42.612).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ICAD is expected to report earnings to rise 175.00% to -5 cents per share on August 06

iCAD ICAD Stock Earnings Reports
Q2'25
Est.
$-0.05
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.07
The last earnings report on May 13 showed earnings per share of -1 cents, beating the estimate of -5 cents. With 94.80K shares outstanding, the current market capitalization sits at 42.43M.
A.I. Advisor
published General Information

General Information

a provider of computer-aided detection solutions

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Computer Peripherals
Address
98 Spit Brook Road
Phone
+1 603 882-5200
Employees
109
Web
https://www.icadmed.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GILT7.090.07
+1.00%
Gilat Satellite Networks Ltd
ASPN5.920.04
+0.68%
Aspen Aerogels
MOBX0.77N/A
+0.57%
Mobix Labs
PSX119.300.05
+0.04%
Phillips 66
PII40.65-0.29
-0.71%
Polaris

ICAD and Stocks

Correlation & Price change

A.I.dvisor tells us that ICAD and HAE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and HAE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
-0.52%
HAE - ICAD
32%
Poorly correlated
+1.10%
HYPR - ICAD
29%
Poorly correlated
-1.59%
CVRX - ICAD
27%
Poorly correlated
+1.03%
RGEN - ICAD
27%
Poorly correlated
+0.66%
BAX - ICAD
26%
Poorly correlated
-0.36%
More